Loss of vision

Loss of vision Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 378 adverse event reports that reference Loss of vision as a reaction term, including 88 reports with a death outcome — a 2330.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 1596, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Loss of vision appears most frequently in reports for Dog (300 reports), Cat (73 reports), Human (3 reports) — with Dog dominating at 300 entries. Within those species, the breeds most often named alongside this reaction are Domestic Shorthair (44), Chihuahua (26), Retriever - Labrador (24). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Loss of vision are Bedinvetmab (42 reports), Milbemycin Oxime + Spinosad (31 reports), Carprofen (25 reports), Afoxolaner (24 reports), with Bedinvetmab appearing alongside this reaction in 42 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.